A survey by ISMP and ECRI highlights the severe impact of drug and equipment shortages on healthcare. Conducted from June 29 to July 27, 2023, it gathered insights from practitioners about shortages affecting medications, single-use supplies, and durable medical equipment. Notably, 44% of respondents reported shortages in hematology and oncology drugs, leading to altered chemotherapy regimens, increased medication error risks, and strained clinical resources. These disruptions compromise patient care quality and pose significant challenges to healthcare operations, underscoring the urgent need for solutions to address supply chain issues.

Alkermes has announced positive topline results from the Vibrance-2 phase 2 study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Alixorexton, formerly referred to as ALKS 2680, is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in phase 2 development for the treatment of narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). – Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – Alixorexton Met the Study's Dual Primary Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Excessive Daytime Sleepiness Compared to Placebo in Patients With Narcolepsy Type 2 – Alixorexton Was Generally Well Tolerated at All Doses Tested Learn more: https://lnkd.in/g8GNYXmY #narcolepsy #orexin #orexinagonist #Alkermes

MASH is at another turning point. With its first-ever approved treatment (Rezdiffra) now established, and GLP-1, Wegovy, recently FDA-approved for patients with moderate-to-advanced fibrosis, MASH care is moving upstream – towards earlier identification and management. Ipsos’ latest PoV explores the new imperatives for pharma companies operating in this space: Monitor the evolution of the MASH patient flow, from timings and methods of diagnosis to HCPs involved in patient care Understand how the use of available treatment options is unfolding Align drug benefits to the unique requirements of specific patient types Read our full PoV: https://lnkd.in/ec7Sgfwm Ipsos has tracked MASH treatment since 2017; the next wave of our MASH Therapy Monitor will assess Wegovy’s impact and Rezdiffra’s evolving role. #MASH #Hepatology #GLP1 #PharmaInsights

MSD has secured an updated FDA label for its breakthrough PAH therapy, WINREVAIR™ (sotatercept-csr k) — now including reduction in hospitalization, lung transplant, and death. Why it matters: This move strengthens Merck’s clinical and strategic edge in pulmonary hypertension. For competitors like Gilead, United Therapeutics, and Janssen, the benchmark just shifted — from improving exercise capacity to demonstrating survival benefit. The update will likely reshape pricing dynamics, reimbursement frameworks, and partnering priorities in rare cardiovascular markets. At Medifirm Intelledge Global, we track such shifts through real-time competitive intelligence, pipeline analytics, and launch strategy insights — helping pharma teams anticipate the next move before it happens. #Merck #CompetitiveIntelligence #PharmaStrategy #PAH #Winrevair #MarketAccess #DrugLaunch #MedifirmIntelledgeGlobal

LucidQuest YouTube > Trending in Respiratory Research: CAL101, LTI-03, Taladegib and More: In this edition of Respiratory Research Updates, we highlight key breakthroughs in pulmonary health. Calluna Pharma’s CAL101 received FDA Orphan Drug Designation for IPF, while Rein Therapeutics resumes its Phase 2 trial of LTI-03 in IPF. Endeavor BioMedicines' Taladegib gained EMA PRIME Designation for IPF treatment. Hanmi Pharma’s partnership with Boehringer Ingelheim expands COPD treatment access in Korea. Otsuka’s Phase 3 trial for MDR-TB begins, and GSK Korea launches the Nucala Auto Injector. MannKind discontinues its NTM lung disease trial, focusing on new formulations. Plus, CalciMedica’s promising data for PAH therapy. Stay tuned for more updates! http://dlvr.it/TPH4BT Subscribe for more! #LucidQuest #PharmaCI

LucidQuest YouTube > Trending in Respiratory Research: CAL101, LTI-03, Taladegib and More: In this edition of Respiratory Research Updates, we highlight key breakthroughs in pulmonary health. Calluna Pharma’s CAL101 received FDA Orphan Drug Designation for IPF, while Rein Therapeutics resumes its Phase 2 trial of LTI-03 in IPF. Endeavor BioMedicines' Taladegib gained EMA PRIME Designation for IPF treatment. Hanmi Pharma’s partnership with Boehringer Ingelheim expands COPD treatment access in Korea. Otsuka’s Phase 3 trial for MDR-TB begins, and GSK Korea launches the Nucala Auto Injector. MannKind discontinues its NTM lung disease trial, focusing on new formulations. Plus, CalciMedica’s promising data for PAH therapy. Stay tuned for more updates! http://dlvr.it/TPGl2r Subscribe for more! #LucidQuest #PharmaCI

LucidQuest YouTube > Trending in Respiratory Research: CAL101, LTI-03, Taladegib and More: In this edition of Respiratory Research Updates, we highlight key breakthroughs in pulmonary health. Calluna Pharma’s CAL101 received FDA Orphan Drug Designation for IPF, while Rein Therapeutics resumes its Phase 2 trial of LTI-03 in IPF. Endeavor BioMedicines' Taladegib gained EMA PRIME Designation for IPF treatment. Hanmi Pharma’s partnership with Boehringer Ingelheim expands COPD treatment access in Korea. Otsuka’s Phase 3 trial for MDR-TB begins, and GSK Korea launches the Nucala Auto Injector. MannKind discontinues its NTM lung disease trial, focusing on new formulations. Plus, CalciMedica’s promising data for PAH therapy. Stay tuned for more updates! http://dlvr.it/TPGl2m Subscribe for more! #LucidQuest #PharmaCI

LucidQuest YouTube > Trending in Respiratory Research: CAL101, LTI-03, Taladegib and More: In this edition of Respiratory Research Updates, we highlight key breakthroughs in pulmonary health. Calluna Pharma’s CAL101 received FDA Orphan Drug Designation for IPF, while Rein Therapeutics resumes its Phase 2 trial of LTI-03 in IPF. Endeavor BioMedicines' Taladegib gained EMA PRIME Designation for IPF treatment. Hanmi Pharma’s partnership with Boehringer Ingelheim expands COPD treatment access in Korea. Otsuka’s Phase 3 trial for MDR-TB begins, and GSK Korea launches the Nucala Auto Injector. MannKind discontinues its NTM lung disease trial, focusing on new formulations. Plus, CalciMedica’s promising data for PAH therapy. Stay tuned for more updates! http://dlvr.it/TPH4B0 Subscribe for more! #LucidQuest #PharmaCI

Encouraging update for the ALK+ lung cancer community—looking forward to topline ALKOVE-1 data on investigational neladalkib for TKI-pretreated advanced ALK+ NSCLC. Gratitude to the patients, caregivers, and researchers; results will need careful, peer-reviewed evaluation. Learn why biomarker testing matters: https://lnkd.in/ggsz29en #ALKpositive #NSCLC #ClinicalTrials #PrecisionOncology #LungCancer